Datapoint: Tivdak Scores FDA Nod for Cervical Cancer

The FDA on Sept. 20 granted an accelerated approval to Seagen Inc. and Genmab A/S’s Tivdak for the treatment of recurrent or metastatic cervical cancer that has continued to progress following chemotherapy. The drug is the first antibody-drug conjugate approved for cervical cancer. Among the most advantaged cervical cancer therapies are Roche’s Avastin, which holds covered or better status for 89% of all insured lives under the medical benefit, Amgen’s Mvasi (a biosimilar to Avastin, also 89%) and Merck’s Keytruda (85%).

SOURCE: MMIT Analytics, as of 9/23/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 29

Datapoint: Nebraska Awards Medicaid Contracts

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 28

Datapoint: Lilly Scores Sweeping Label Expansion for Retevmo

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 27

Datapoint: Judge Says United Can Complete Change Healthcare Deal

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today